Samsara BioCapital Group Increases Stake in Alumis Inc. with $15.2M in Recent Purchases
ALMS has more than doubled off its 52-week low of $2.76 on elevated volume (1.9× avg).
Summary
An institutional investor group, Samsara BioCapital, significantly increased its stake in Alumis Inc. with over $15.2 million in recent share purchases, including participation in a public offering, at prices well below the current market value.
Key Events · Ownership and Investor Activity · ALMS
-
Significant Share Accumulation
Samsara Opportunity Fund, part of the Samsara BioCapital group, purchased an aggregate of $15,209,937.96 worth of Alumis Inc. common stock between November 26, 2025, and January 9, 2026.
-
Participation in Public Offering
The most recent acquisition included 588,235 shares purchased at $17.00 per share from underwriters of the company's January 2026 public offering.
-
Increased Beneficial Ownership
Srinivas Akkaraju, who controls the Samsara entities, now beneficially owns 6,345,219 shares, representing 5.4% of the outstanding common stock.
-
Purchases Below Current Market Price
The shares were acquired at prices ranging from $7.31 to $17.00, significantly below the current stock price of $22.56, indicating strong conviction from the investor.
Analysis · ALMS · Life Sciences
Samsara BioCapital, an institutional investor group led by Srinivas Akkaraju, has significantly increased its beneficial ownership in Alumis Inc. through a series of open market purchases and participation in a recent public offering. The group acquired over $15.2 million worth of shares between late November 2025 and early January 2026, at prices ranging from $7.31 to $17.00 per share. This substantial investment demonstrates strong conviction from a key institutional holder, especially given that the purchases were made at prices considerably below the current trading price near the 52-week high. Investors may view this as a vote of confidence in Alumis's future prospects.
At the time of this filing, ALMS was trading at $22.56 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.8B. The 52-week trading range was $2.76 to $23.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.